Nowadays, in the postgenome time, many "-ome" studies have emerged including proteome, transcriptome, interactome, metabolome, adipokinome, connectome. In 
Recent studies provide evidence that morbid obesity is a major burden of human health that plays a pivotal role in the development of cardiometabolic diseases (CMD) ( Table 1) , also non-alcoholic steatohepatitis, obstructive sleep apnea syndrome, polycystic ovary syndrome, and Alzheimer's disease. These are among the major health, social and economic evils of Homo sapiens recens, globally. The World Health Organization has predicted a "globesity epidemic" with more than one billion adults being overweight (BMI over 25 kg/ m 2 ) and at least 400 million of these being clinically obese (BMI over 30 kg/m 2 ). Moreover, CMD are associated with cognitive and mood disorders including Alzheimer's disease and depression (1) (2) (3) (4) (5) (6) (7) (8) . Arguably, we have learned more about the molecular control of food intake and energy homeostasis, particularly, the role played by adipose tissue in the pathogenesis of various diseases, including CMD. Cumulatively, such an adipocentric approach (8-13) has integrated the traditional cardovascular risks (age, sex, smoking, hypertension, dyslipidemia, homocysteinemia) and abdominal obesity and related features of the metabolic syndrome, hence, global cardiometabolic risk (14-16, cf. 17-19) .
IMPLICATION OF NGF AND BDNF IN CARDIOMETABOLIC DISEASE: RESULTS OF A DREAM
During his student life at the Medical University, Varna, Bulgaria, one of us (GNC) used to work four years (1962) (1963) (1964) (1965) (1966) as research associated at the Department of Pharmacology. It was that period of time when he for the first time "met" Professor Rita Levi-Montalcini, reading her first papers on nerve growth factor (NGF 
NGF-OME PROJECT
At the beginning of this century the Human Genome Project was finalized estimating over 30 000 genes encoding more than 100 000 functionally distinct proteins. As happened usually, one solved problem delivered many unsolved ones. Thus in the postgenome time, many "-ome" projects have emerged including proteome, transcriptome, interactome, metabolome, adipokinome, connectome. In this vein, all the actions of NGF in health and disease are herein referred to as NGF-ome.
Since 1951 when the NGF was discovered followed by the discovery of other neurotrophins including brain-derived neurotrophic factor (BDNF) ( Table 2) , it has been increasingly recognized that life at neuronal level requires trophic support (21) (22) (23) (24) (25) (26) .
As often occurs, the framework of an initial conception of the role of a newly discovered biomolecule extends in the light of emerging findings. This was also the case for NGF. During some 25 years after its discovery, there have been few reasons given to indicate that NGF acts on nonneuronal cells. * Two peptides derived from the pro-NGF: LIP1 is a 29-amino acid peptide, LIP2 is a 38-amino acid peptide, both corresponding to sequences within the NGF (47-49).
Metabotrophic NGF and BDNF
Thus, in 1975, Aloe and Levi-Montalcini have made an experiment demonstrating that treatment of newborn rats with NGF caused an increase in the number of mast cells in various organs. These findings (20) have triggered the study on neuroimmune interaction, leading to today's accumulation of evidence that NGF is not only for neuronal life. Indeed, "the submerged areas of the NGF iceberg loom very large", Rita Levi-Montalcini stated in her Nobel prize lecture reviewing 35 years of research on NGF (22) .
Cumulatively, studies in the past three decades have revealed that the neurotrophins NGF and BDNF are not only stimulating for nerve growth and survival, but also exert trophic effects over (i) immune cells, acting as immunotrophins (20, 27) , (ii) keratinocytes, enterocytes, prostate and breast epithelial cells, acting as epitheliotrophins (see 21) , (iii) endothelial cells, acting as angiogenic factors (28) , and (iv) glucose, lipid and energy homeostasis, pancreatic beta cell and vascular system as well as wound healing, and thus designated metabotrophins (from Greek metabole and trophe, nutrition, means "nutritious for metabolism") (8, 18) .
METABOTROPHIC NGF AND BDNF
Noteworthy, (i) pancreatic beta cells secrete NGF and express its receptor, tyrosine-kinase A (TrkA), these findings being implicated in the pathogenesis of diabetes mellitus (29) (30) (31) (32) , and (ii) systemic and/or local levels of the major metabotrophins, NGF and BDNF, are altered (reduced or, probably, compensatory elevated) in the major CMD (coronary atherosclerosis, obesity, diabetes, metabolic syndrome) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) , including acute coronary syndromes (43) , and (iii) administration of BDNF improves both energy and glucose homeostasis (44, 45) . Metabotrophic effects of NGF and BDNF are summarized in Table 3 .
CONCLUSION
The discussed findings may implicate the metabotrophic expression of NGF-ome in the pathogenesis of cardiometabolic and neurodegenerative diseases. This hypothesis may open new approaches in the search of exogenous metabotrophic factors, such as (i) small molecules boosting secretory and/ or signaling pathways of both NGF and BDNF (8, 18, 19) , (ii) incretin mimetics and receptor agonists, because the insulinotropic hormone glucagon-like peptide-1 (GLP-1) and exendin-4, a GLP-1 receptor agonist, exert both neurotrophic and metabotrophic effects (46) , and (iii) agents interfering with vascular endothelium growth factor (28) .
The present challenge is therefore to learn more about the metabotrophic potential of human NGF-ome in the pathogenesis and therapy of cardiometabolic and neurodegenerative diseases.
